Women's Health

GLP-1s, Pregnancy and Fertility: What Women Planning a Family Need to Know (2026)

By the US Health Digest editorial team · Updated July 21, 2026

GLP-1 weight-loss medications are not for use in pregnancy, and clinicians advise stopping them in advance of trying to conceive — your prescriber will advise the washout period for your specific medication. If you are planning a family, that conversation belongs at the start of treatment, not after a positive test. And if you do become pregnant while taking one, the steps are simple: contact your clinician promptly, and report the exposure through the FDA's MedWatch program.

The hard rule: these medications are not for use in pregnancy

On this one point, the guidance is settled. GLP-1 medications prescribed for weight loss are not used during pregnancy, and prescribers treat pregnancy — or active plans to become pregnant — as a reason not to start, and a reason to stop.

Part of the reason is what the evidence base does and does not cover. In the STEP 1 trial of semaglutide 2.4 mg, roughly three-quarters of the 1,961 participants were women — but it was a weight-loss trial, not a pregnancy-safety trial, and no trial will ever be run to answer the pregnancy question directly. Where evidence is absent, prescribing practice is appropriately conservative: not in pregnancy, full stop.

Stopping before you try to conceive

Because these medications stay in the body for a while after the last dose, clinicians advise stopping them some time before you begin trying to conceive — not the day you decide to start. Your prescriber will advise the washout period for your medication; we deliberately do not publish a number here, because the right answer depends on which drug you take and on your circumstances.

Two practical implications follow. First, if a family is on your horizon in the next year or so, say so at intake — it changes the plan. Second, expect weight regain to be part of the honest conversation about stopping; our review of semaglutide trial results in women covers what the trial data show about what happens when treatment ends.

Why the intake question is a legitimacy test

Here is a useful side effect of the hard rule: it gives you a fast way to judge any telehealth service. A legitimate GLP-1 program must ask whether you are pregnant, breastfeeding, or planning pregnancy, because the answer can disqualify you. A service that never asks is not screening you — it is processing your payment. That question's presence or absence is one of the clearest markers separating medical services from subscription funnels, a distinction we walk through step by step in how GLP-1 telehealth actually works.

The concern is not hypothetical. The FDA has raised specific concerns about unapproved and compounded GLP-1 products, and the corner-cutting that produces vague sourcing tends to travel with the corner-cutting that skips pregnancy screening. If a service failed to ask, treat that as disqualifying — whatever else it promises.

The fertility wrinkle to raise with your clinician

There is a second conversation worth having, and it cuts the other way. Meaningful weight loss can affect ovulation and cycle regularity — this is commonly discussed in clinical practice, particularly for women whose cycles have been irregular. For some women, losing weight on a GLP-1 changes their fertility picture while they are still taking a medication that is not for use in pregnancy.

We are deliberately qualitative here: how likely this is varies from woman to woman, and it is a question for your clinician, not a statistic to be quoted at you. The practical takeaway is simply that "I probably can't get pregnant anyway" is not a plan while on these medications.

Contraception is a standard part of the conversation

That is why contraception is a normal, expected topic when a GLP-1 is prescribed to a woman who could become pregnant — not an intrusion. A good prescriber will ask what you are using and revisit the question at check-ins; if yours never has, raise it yourself at the next one. Our GLP-1 FAQ for women collects the related questions women ask most, and our side-effects guide covers what else to flag between visits.

If you become pregnant while taking a GLP-1

It happens, and the response is straightforward rather than alarming:

• Contact your prescribing clinician promptly. They will advise you on stopping the medication and on next steps for your pregnancy care. Do not simply keep taking it while you wait for an appointment window — make the contact now.
• Report the exposure to the FDA's MedWatch program. MedWatch is the FDA's safety-reporting system for drugs on the market. Reports like these are how the real-world evidence on pregnancy exposure accumulates — evidence the original trials were never going to provide.

Planning a family and treating obesity are both legitimate medical goals. They just need to be sequenced — and the clinician who prescribes your GLP-1 is the person to sequence them with.